Suwon-si, South Korea

Woo Seob Shin

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 5.5

ph-index = 1


Location History:

  • Suwon-Si, KR (2022)
  • Gyeonggi-do, KR (2022 - 2024)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Woo Seob Shin

Introduction

Woo Seob Shin is a notable inventor based in Suwon-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds. With a total of 4 patents to his name, his work has garnered attention for its potential applications in medicine.

Latest Patents

One of Woo Seob Shin's latest patents involves the creation of a mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide. This invention is characterized by its excellent stability, solubility, and bioavailability, making it effective both as a standalone treatment and in combination with other drugs. The crystalline form of this compound is noted for its high purity and the innovative process for its preparation.

Career Highlights

Woo Seob Shin is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on the development of advanced pharmaceutical compounds that can improve patient outcomes.

Collaborations

Throughout his career, Woo Seob Shin has collaborated with several talented individuals, including Sang Ho Oh and Jong Gyun Kim. These collaborations have contributed to the successful development of his innovative patents.

Conclusion

Woo Seob Shin's contributions to the field of pharmaceuticals through his innovative patents highlight his expertise and dedication to improving medical treatments. His work continues to pave the way for advancements in drug development and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…